The Kable

The Kable

Friday Kable

๐Ÿ’‰ A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business

#459 | Malarial protein discoveries; A phage diet for cells; Migraines in your genes

Ria's avatar
Vinod's avatar
Ria
and
Vinod
Oct 27, 2023
โˆ™ Paid
Share

Hello, and welcome to our free Friday edition of The Kable. Today, we kick things off with good news on the respiratory virus vaccine front. Pfizer and BioNTech have announcedย positive results from phase 1/2 studies of their mRNA-based combo vaccine, which generated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. A phase 3 tโ€ฆ

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
ยฉ 2025 The Kable
Privacy โˆ™ Terms โˆ™ Collection notice
Start writingGet the app
Substack is the home for great culture